01 Apr 2021
Lonza Completes Divestment of Two Sites to NextPharma
  • Completion of sale of Lonza sites in Ploermel (FR) and Edinburgh (UK)
  • A seamless ownership transfer process remains a priority

A French version of this release is also available

Quote from Gordon Bates, President and Head of Small Molecules, Lonza:

“The strategic divestment of our Ploermel and Edinburgh sites will enable NextPharma to benefit from operational synergies and optimize existing expertise and technologies. In this context, as we close the divestment process, we are confident that NextPharma is well placed to develop and grow both sites to their full potential. We wish to thank the leadership teams and employees at the Ploermel and Edinburgh sites for their continuing dedication and professionalism during the transition period.”

Quote from Peter Burema, CEO of NextPharma:

“We are very excited at adding two new centers of excellence, at Ploermel and Edinburgh, to NextPharma's manufacturing network, allowing us to further broaden our technology offering for both our existing and new customers. These technologies, combined with the know-how and expertise of the employees at both sites, will provide additional solutions for drug formulations which will benefit patients across the world. On behalf of the whole NextPharma team, I welcome our new colleagues, and together we look forward to continuing to further develop and grow NextPharma as a leading and well-respected European CDMO.”

Basel, Switzerland and London, United Kingdom, 1 April 2021 – Lonza announced today the completion of the divestment of its Ploermel (FR) and Edinburgh (UK) sites to NextPharma.

The agreement between both parties was previously announced on 19 January 2021.